Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with participation from existing investors RA Capital Management, Perceptive Advisors, Vivo Capital LLC, and Granite Point Capital Management L.P.
